Daclatasvir 30mg Tab
Trade Name
Prescriber Category
:
:
A/KK
Department
Antimicrobial Restriction
:
:
MED (ID)
N/A
INDICATION (BLUE BOOK / UKK)
To be used in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.
DOSING FOR ADULTS GUIDE [DIAMS HSgB]
With ATV+RYV:
30 mg PO q24h
With other RTV boosted PIs:
60 mg PO q24h
With DTG or RAL:
60 mg PO q24h
With EFV or NVP:
90 mg PO q24h
*Use in combination with Sofosbuvir
RENAL DOSE ADJUSTMENT IN ADULTS GUIDE [DIAMS HSgB]
No dosage adjustment required.
IV TO PO GUIDE [DIAMS HSgB]
N/A
EXTENDED INFUSION GUIDE [DIAMS HSgB]
In-progress
SPECIAL MONITORING & PRECAUTION GUIDE [DIAMS HSgB]
In-progress
ALTERNATIVE DOSING (BLUE BOOK / HSgB DRUG LIST)
60 mg once daily, to be taken orally with or without meals.
Dose recommendation when taking concomitant medicines:
i. Strong inhibitors of cytochrome P450 enzyme 3A4 (CYP3A4): Reduce dose to 30 mg once daily when co-administered with strong inhibitors of CYP3A4.
ii. Moderate inducers of CYP3A4: Increase dose to 90 mg once daily when co-administered with moderate inducers of CYP3A4.
Daclatasvir must be administered in combination with other medicinal products for the treatment of hepatitis C infection. Dose modification of daclatasvir to manage adverse reactions is not recommended